Keyword Tag Sort by

Categories: Lung Cancer Drugs Tumors Lungs FGF-2 PD173074 SCLC

Drug Shrinks Lung Cancer Tumours in Mice

Researchers plan to take treatment to clinical trials.

A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer.

One in five people with lung cancer have small cell lung cancer and only three per cent of these people are expected to survive for five years. With this form of lung cancer, tumours spread quickly so it is rarely possible to remove the tumours surgically. Because of this, small cell lung cancer is treated with chemotherapy, with or without additional radiotherapy. Initially, the treatment often appears to work, reducing the size of the tumours. However, the tumours usually grow back rapidly and then become resistant to further treatment.

The researchers behind today's study have identified a drug that, in some mice, was able to completely shrink tumours away. In the mouse models, it was also able to stop tumours from growing and it helped other forms of chemotherapy to work more effectively. If the drug proves successful in humans, the researchers hope that it could help patients with this kind of lung cancer to live longer.

In small cell lung cancer, tumours spread quickly because the tumour cells grow and divide faster than normal cells. Previous research carried out by the Imperial team showed that these tumour cells proliferate faster because they are fuelled by a growth hormone called FGF-2. This growth hormone also triggers a survival mechanism in the tumour cells that makes them become resistant to chemotherapy.

In today's study, the researchers looked at the effect of a drug called PD173074, which blocks the receptor that FGF-2 uses to attach to the tumour cells. The drug stopped cancer cells from proliferating and from becoming resistant to treatment in 'test-tube' laboratory models. In one animal model of small cell lung cancer, the drug eliminated tumours in 50% of mice and in a second, similar mouse model, the drug enhanced the effect of standard chemotherapy.

Small cell lung cancer can be difficult to treat
with standard chemotherapy.
Imperial College London)

Professor Michael Seckl, corresponding author of the study who heads the Section of Molecular Oncology and Lung Cancer Research at Imperial College London, said: "Lung cancer is the most common cancer killer in the world and over 100 people in the UK are diagnosed with the disease every day. Around one in five of those people will have small cell lung cancer. Although it responds to chemotherapy initially, the tumours soon become resistant to treatment and sadly nearly all people with the disease do not survive.

"We urgently need to develop new treatments for this disease. Our new research in mice suggests that it may be possible to develop the drug PD173074 into a new targeted therapy for small cell lung cancer. We hope to take this drug, or a similar drug that also stops FGF-2 from working, into clinical trials next year to see if it is a successful treatment for lung cancer in humans. An added bonus of this drug is that it could be taken orally, which would make it less invasive than some other forms of cancer therapy," added Professor Seckl.

The researchers first studied the effect of PD173074 in the lab, on cells taken from human tumours. The drug stopped cells from proliferating and prevented FGF-2 from triggering their survival mechanism, so the cells could be killed with standard chemotherapy agents. The effect of the drug was dose-dependent, so the more drug the researchers added to the cells, the less the cells proliferated.

The researchers then studied PD173074 in mice using two different types of human small cell lung cancer tumours. They tested the drug on its own and alongside the standard chemotherapy agent cisplatin, which is frequently used to treat patients with the disease. In the first mouse model, PD173074 given on its own killed off tumours in 50 per cent of the mice and these mice remained disease-free for at least one year. In the second mouse model, both PD173074 and cisplatin alone slowed down tumour growth. When the drugs were combined, they slowed down tumour growth significantly faster than either drug on its own.

The researchers also used PET scanning to show that the drug reduced DNA synthesis in the tumours, which indicates that the drug was preventing cell proliferation. The researchers also found that the rate of cell death, or apoptosis, in the tumours increased after the drug was given to the mice.

PD173074 was developed in 1998 to stop blood vessels from forming around tumours. Today's research is the first to show this drug has a therapeutic effect on tumours in mice.

The research was funded by the Cancer Treatment and Research Trust, Cancer Research UK and the UK Department of Health.

The paper: 
Olivier E. Pardo, John Latigo, Rosemary E. Jeffery, Emma Nye, Richard Poulsom, Bradley Spencer-Dene, Nick R. Lemoine, Gordon W. Stamp, Eric O. Aboagye, and Michael J. Seckl

Cancer Res first published on November 10, 2009 as doi:10.1158/0008-5472.CAN-09-1576
Corresponding author: Professor Michael Seckl, Imperial College London

Contact: Lucy Goodchild, Press Officer, Imperial College London, Tel: +44 (0)20 7594 6702 or ext. 4670, E-mail:

Source: Imperial College London

Photos (2)  [ view all photos ]

Small cell lung cancer can be difficult to treat with standard chemotherapy. (Imperial College London)

(Imperial College London)

Related News:

Graphene plasmonics beats the drug cheats 14 January 2013, 02:11
Wonder material graphene could help detect the presence of drugs or toxins in the body or...

Mayo Study: Common Diabetes Drug May Treat Ovarian Cancer 4 December 2012, 01:07
Diabetic patients with ovarian cancer who took the drug metformin for their diabetes had a better...

Breast Cancer Drug Could Halt Other Tumours 7 November 2012, 06:03
A drug commonly used in treating breast cancer could have far wider benefits, offering a new way...

Aspirin a viable treatment for serious blood clots, study shows 5 November 2012, 01:50
Low-dose aspirin is a cheap and effective way to prevent potentially deadly blood clots in the...

New Gene Test Flags Risk of Serious Complications in Sarcoidosis 12 October 2012, 04:22
Researchers at the University of Illinois Hospital & Health Sciences System have identified...

Reining in Metastatic Cells 9 October 2012, 14:22
Most cancer deaths are caused by metastases, secondary tumors seeded by cells that escape from...

New Drug Shrinks Brain Tumours in Melanoma Patients 8 October 2012, 04:28
Australian researchers have given hope to patients with advanced melanoma by showing that a new...

Blocking Tumor-Induced Inflammation Impacts Cancer Development 3 October 2012, 13:40
How tumors exploit microflora and immune cells to fuel growth.Researchers at the University of...

Penn-developed Mouse Model of Debilitating Lung Disease Suggests... 3 October 2012, 13:20
PHILADELPHIA — LAM, short for pulmonary lymphangioleiomyomatosis, affects about 1 in 10,000...

Cardiac medication may reduce stiffness caused by certain muscle... 3 October 2012, 06:25
Mexiletine, a decades-old drug previously used to treat abnormal heart rhythms, has been used to...

Credits / Source:

Small cell lung cancer can be difficult to treat with standard chemotherapy. (Imperial College London)

(Imperial College London)